UNITED THERAPEUTICS CORPORATION
About UNITED THERAPEUTICS CORPORATION
United Therapeutics Corporation is a public benefit corporation focused on developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Founded in 1996 and headquartered in Silver Spring, Maryland, the company has six FDA-approved therapies treating pulmonary arterial hypertension (PAH) and related conditions. It operates in the pharmaceutical manufacturing sector and is listed on NASDAQ under UTHR. The company emphasizes innovation for rare, deadly diseases and was the first publicly-traded biotech or pharmaceutical firm to adopt public benefit corporation status.
- ๐ United Therapeutics Corporation
- ๐ United Therapeutics Corporation - 2026 Company Profile & Competitors - Tracxn
- ๐ United Therapeutics Corporation - UTHR Stock Price Quote & News - M1
- ๐ United Therapeutics Investor Relations
- ๐ United Therapeutics Corporation to Present at Upcoming Investor Conferences
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- Public benefit corporation with mission to develop therapies expanding transplantable organs.
- Six FDA-approved therapies for pulmonary arterial hypertension.
- Completed $2.50B Post-IPO Debt round in 2025.
- Acquired Miromatrix Medical for $91M and Thymmune Therapeutics for $140M.
- Authorized $2B share repurchase program through 2027.
Ask StreetZero about UNITED THERAPEUTICS CORPORATION
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account